List of Afinitor Disperz drug patents
Afinitor Disperz is owned by Novartis Pharm.
Afinitor Disperz contains Everolimus.
Afinitor Disperz has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Afinitor Disperz are:
- US8778962
- US8778962*PED
- US8617598
Afinitor Disperz was authorised for market use on 29 August, 2012.
Afinitor Disperz is available in tablet, for suspension;oral dosage forms.
Afinitor Disperz can be used as treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; adjunctive treatment of patients with tsc-associated partial-onset seizures.
The generics of Afinitor Disperz are possible to be released after 10 April, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778962 | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(11 months ago) | |
|
US8778962
(Pediatric) | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(5 months ago) | |
| US8617598 | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Sep, 2022
(4 months ago) | |
|
US8617598
(Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Mar, 2023
(a month from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 10, 2025 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 29 August, 2012
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Adjunctive treatment of patients with tsc-associated partial-onset seizures
Dosage: TABLET, FOR SUSPENSION;ORAL
AFINITOR DISPERZ family patents
16
Japan
15
Norway
15
European Union
14
United States
11
Israel
10
Spain
10
China
9
Hong Kong
9
Lithuania
9
Portugal
9
Russia
8
Cyprus
8
Denmark
7
Slovenia
6
Poland
5
Slovakia
5
Czech Republic
4
Korea, Republic of
4
Mexico
4
Canada
3
Brazil
3
Luxembourg
3
United Kingdom
3
New Zealand
3
Taiwan, Province of China
2
Hungary
2
Argentina
2
South Africa
1
Austria
1
Australia
1
Malaysia
1
Germany
1
Colombia
1
Peru
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic